title: Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy.
authors.forename: Susumu
authors.initials: S
authors.lastname: Ogawa
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nako
authors.forename: Masashi
authors.initials: M
authors.lastname: Okamura
authors.forename: Miho
authors.initials: M
authors.lastname: Senda
authors.forename: Takefumi
authors.initials: T
authors.lastname: Mori
authors.forename: Sadayoshi
authors.initials: S
authors.lastname: Ito
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000419:Albuminuria / Q000188:drug therapy* / Q000209:etiology; D000577:Amides / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D044466:Asian People; D001794:Blood Pressure / Q000187:drug effects; D018932:Chemokine CCL2 / Q000652:urine; D003404:Creatinine / Q000652:urine; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000652:urine; D003928:Diabetic Nephropathies / Q000150:complications*; D005260:Female; D005650:Fumarates / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D015850:Interleukin-6 / Q000652:urine; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; C111835:CCL2 protein, human; D018932:Chemokine CCL2; D005650:Fumarates; D015850:Interleukin-6; C446481:aliskiren; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003404:Creatinine; D003849:Deoxyguanosine